Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual PMBL (Ismigen) in moderate to very severe COPD
2007-000006-67Phase 4Completed
- Sponsor
- Lallemand Pharma
- Start
- Jun 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) comparing Ismigen with Placebo (2 arms). Primary endpoint: Number of exacerbations in 12-month observation period. Started Jun 2009; status: completed.
02
Drugs
polyvalent mechanical bacterial lysate
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on 2007-000006-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000006-67.